Why your patent portfolio is your most undervalued fundraising asset

Introduction

There's a question investors ask early in due diligence that most founders aren't ready for. It's not about revenue, team, or market size. It's: "What stops someone from copying this?"

Your answer to that question, and how quickly and credibly you can answer it, will shape the rest of the conversation more than almost anything else.

Patents are one of the most direct answers you can give. Not because a patent magically prevents competition, but because it signals something VCs care deeply about: that you've thought seriously about defensibility, taken a concrete step to secure it, and created a legal moat that makes your technology harder to replicate.

‍

What does "patent pending" signal to investors?

A common misconception is that patents only matter once they're granted. That can take three to five years at the EPO. Investors aren't waiting for that.

What changes the fundraising conversation is the filing, specifically the priority date that comes with it. From the moment your application is filed, you have a documented, timestamped claim on your invention. You're "patent pending." That status tells investors three things: you've identified what's novel about your technology, a qualified attorney has reviewed it, and nobody else can patent the same idea from this point forward.

At seed and pre-Series A, that's enough. The patent doesn't need to be granted. It needs to exist.

‍

The valuation effect is real

Studies of European tech companies consistently show that patent-protected startups raise at higher valuations at Series A than comparable unprotected companies. The effect is most pronounced in deep-tech, life sciences, medtech, and hardware, where the technology itself is the product. But it shows up in SaaS and AI too, particularly where the underlying algorithm or system architecture is genuinely novel.

The mechanism is straightforward: investors are pricing risk. An unprotected technology can be copied by a well-funded competitor tomorrow. A patent-protected technology comes with legal recourse. That difference in risk profile flows directly into valuation.

‍

When should you file a patent?

The honest answer is: earlier than you think.

Most founders wait until the product is finished. That's the wrong mental model. A patent doesn't protect a finished product. It protects an invention. And an invention exists the moment you have a working description of something novel, regardless of whether it's been built.

Filing early also protects you from a risk most founders don't see coming: prior art from your own disclosures. Every time you demo your product at an event, publish a blog post about how it works, or talk to a journalist, you're creating public disclosure. In most jurisdictions, public disclosure starts a clock. In Europe, there's no grace period. Disclose before filing and you may have invalidated your own patent.

‍

What do investors actually look for in a patent?

A patent portfolio doesn't need to be large to be valuable. One well-drafted patent on the core technical mechanism is worth more than five patents on peripheral features.

What sophisticated investors look for is alignment: does your patent protect the thing that actually creates the defensible advantage? A biotech company whose core IP is in a manufacturing process should have patents on that process. A hardware company whose moat is a specific sensing mechanism should have claims that cover that mechanism broadly, not just the exact version they built today.

This is where working with a qualified attorney makes a measurable difference. The scope of protection in a granted patent is determined by how the claims are drafted, not by how good the underlying technology is. A narrow claim is easy to design around. A broad claim, properly supported by the specification, is a genuine moat.

‍

The practical takeaway

If you're raising in the next twelve months, file before you start the process. Not because investors will ask for it on day one, some won't, but because having a pending application changes how you answer the defensibility question. Instead of "we're planning to file," you can say "we filed in January, here's the application number." That's a different conversation.

The filing cost is a fraction of a single investor meeting. The signalling value persists for years.

‍

Conclusion

A patent portfolio is a fundraising asset before it's a legal one. The priority date you lock in today changes the conversation you have with investors tomorrow. File before the round, not after.

File your patent before your next investor meeting.

‍

Frequently asked questions

‍

Does a startup need a granted patent to impress investors?

No. Most investors at seed and Series A don't expect a granted patent. The examination process takes three to five years, and investors know that timeline doesn't match an early-stage company. What they look for is a filed application with a priority date. That's verifiable, documented, and signals a different level of seriousness than a plan to file.

‍

How does a patent improve a startup's valuation?

Investors price defensibility into their models. A company without IP protection is valued on operational speed: they win only as long as they stay ahead. A company with a patent is valued on structural advantage: the technology is legally protected regardless of how fast a competitor moves. Studies of European tech startups consistently show that patent-protected companies raise at higher valuations than otherwise comparable unprotected ones.

‍

What's the risk of disclosing your invention before filing?

In Europe, there's no grace period for the inventor's own disclosures. If you publicly describe how your invention works before filing, whether at a demo day, in a blog post, or in an investor meeting without an NDA, you may permanently forfeit the right to patent it. Filing before any public disclosure is the single most important timing decision in early-stage IP strategy.

‍

How many patents does a startup actually need?

Fewer than most founders think. One well-drafted patent on the core technical mechanism is more valuable than several patents on peripheral features. What matters is that the patent covers the thing that actually creates the competitive advantage. A single well-scoped application, properly drafted by a qualified attorney, is a stronger asset than a broad portfolio of narrow or poorly drafted claims.